Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AN2-502998 · 1 trial · 1 indication
Incidence, relatedness, and severity of adverse events
Incidence of physical exam abnormalities
Incidence of changes in blood pressure, pulse, respiratory rate, and temperature
Incidence of changes in 12-lead ECG parameters from baseline
Incidence of changes in clinical laboratory measurements from baseline
Incidence, relatedness, and severity of adverse events
Incidence of physical exam abnormalities
Incidence of changes in blood pressure, pulse, respiratory rate, and temperature
Incidence of changes in 12-lead ECG parameters from baseline
Incidence of changes in clinical laboratory measurements from baseline
Determination of the maximum plasma concentration (Cmax)
Determination the time to maximum plasma concentration (Tmax)
Determine the apparent terminal half-life (t½)
Area under plasma concentration-time curve from zero to a designated dosing interval
Apparent plasma clearance of drug after extravascular administration CL/F
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose (SAD) | EXPERIMENTAL | Participants will be randomized in a 3:1 ratio to receive a single dose of either AN2-502998 or placebo. |
| Multiple Ascending Dose (MAD) | EXPERIMENTAL | Participants will be randomized in a 3:1 ratio to receive multiple doses of either AN2-502998 or placebo. |
| Name | Type | Description |
|---|---|---|
| AN2-502998 | DRUG | Oral Capsule |
| Placebo | DRUG | Oral Capsule |
Inclusion Criteria: 1. Male or female aged 18 to 55 years, inclusive, at Screening 2. Willing and able to provide written informed consent 3. Willing and able to comply with all trial assessments and adhere to the protocol schedule 4. BMI between ≥18 and \<32 kg/m2 (inclusive); BMI is calculated as...
AN2-502998 is an oral small molecule drug candidate developed by AN2 Therapeutics, Inc. It has been evaluated in a first-in-human Phase 1 clinical trial in healthy adult volunteers. The specific disease indications being pursued for AN2-502998 have not been publicly disclosed.
AN2-502998 is being developed by AN2 Therapeutics, Inc., which trades on the Nasdaq under the ticker symbol ANTX. The company is the sponsor of the clinical program evaluating this oral small molecule candidate.
AN2-502998 is in Phase 1 development. Its first-in-human Phase 1 trial has been completed. The drug is investigational and has not been approved by the FDA for any indication.
AN2-502998 has been studied in one clinical trial: NCT07024589, a first-in-human Phase 1 trial of oral AN2-502998. The trial enrolled 72 healthy adult volunteers in Australia and has been completed. It was randomized, double-blind, and controlled.
AN2-502998 does not yet have a disclosed therapeutic use. It has only been tested in healthy volunteers in a completed Phase 1 trial, and the specific disease indications it may treat have not been publicly announced.